Cystatin C and adiponectin in diabetics with and without coronary artery disease

Background: Patients with type 2 diabetes have a high incidence of coronary artery disease, which is even higher among those with renal failure. Serum levels of cystatin C are used to assess renal function and is a potential cardiovascular risk factor. Adiponectin is an anti-atherogenic factor. Aim: To measure cystatin C and adiponectin in type 2 diabetic patients witha and without coronary artery disease. Material and Methods: Nine diabetic patients with coronary artery disease aged 76 +/- 10 years, 20 diabetics without coronary artery disease aged 61 +/- 5 years and 20 non diabetic subjects aged 57 +/- 10 years, were studied. Results: Serum levels of cystatin C (mg/L)were 1.5 (range 0.89-2.19), 0.81 (range 0.71-1.08) and 0.68 mg/L (range 0.55-0.75) in diabetics with and without coronary artery disease and controls, respectively (p<0.0001). No differences in adiponectin between groups and no association between cystatin C and adiponectin, were observed. No association between both parameters and body mass index or glycosilated hemoglobin A1c was observed. Cystatin C had a positive correlation with serum creatinine (r = 0.57 p<0.001). conclusions: diabetics with coronary artery disease have higher levels of cystatin C, that are closely correlated with serum creatinine levels (Rev Med Chile 2009; 137: 729-36).